Lupin restructures, transfers API division and modifies OTC business sale

** Lupin Limited (BSE: LUPIN) today announced a strategic restructuring involving the transfer of its API R&D Division to Lupin Manufacturing Solutions Limited (LMSL), a wholly-owned subsidiary, via a slump sale. The transfer, expected to be completed by April 30, 2025, is subject to customary conditions and regulatory approvals. The consideration for the API R&D division transfer is expected to range from INR 175 million to INR 225 million.